Plain-English fact sheet
BPC-157
Also known as Body Protection Compound 157
BPC-157 is not FDA approved, and most published evidence is from animal or laboratory research rather than high-quality human trials.
Quick answer
BPC-157 is often promoted for injury or gut healing, but it is not an FDA-approved medicine and reliable human clinical evidence is extremely limited.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is BPC-157?
BPC-157 is a synthetic sequence described as being derived from a gastric protein fragment.
Claims about healing are largely extrapolated from animal and laboratory studies, which cannot show that the same benefits or risks apply to people.
Why are people interested in it?
Online discussions frequently mention tendon, ligament, muscle, bone, nerve, and gastrointestinal recovery.
The gap between confident marketing and sparse human evidence is the central fact readers should understand.
Current regulatory status
BPC-157 is not FDA approved. FDA lists it among bulk substances for which compounded products may present significant safety risks and for which safety information is limited.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Preclinical models of tissue injury and gastrointestinal conditions
Evidence snapshot
Most cited work is preclinical. There is no mature body of randomized human trials establishing safety and effectiveness for common promoted uses.
Potential benefits being researched
- Animal and laboratory studies have reported signals related to tissue repair and inflammation.
- Those findings are hypotheses for human research, not proven patient benefits.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- Human short- and long-term safety are poorly characterized.
- FDA notes possible immune reactions, peptide-related impurities, and difficulty characterizing the active ingredient.
- Unapproved products may introduce contamination, incorrect-strength, sterility, or mislabeling risks.
What we still do not know
- Whether animal findings translate to meaningful human benefits
- Long-term safety, cancer-related signaling concerns, interactions, and reproductive risks
- A reliable adverse-effect rate or risk profile
- Whether products sold under the name consistently contain the claimed substance
Plain-English takeaway
BPC-157 is a striking example of online certainty outrunning human evidence. Preclinical findings are not a substitute for controlled trials or regulatory review.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA: bulk substances that may present significant safety risks
FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.
- 2ClinicalTrials.gov studies: BPC-157
Current and completed registered clinical studies.
- 3PubMed research: BPC-157
Peer-reviewed literature indexed by the National Library of Medicine.